Definitive Contract 75N91024C00004

Award Date 2/15/24
Potential Completion Date 8/14/25
Potential Value $300K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Francisco, CA 94107, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
34
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a "Phase 0" pilot program intended to encourage small businesses to develop innovative and...
This is a $355,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to Petri Bio Inc., a small business, under the Small Business Innovation Research (SBIR) Phase I program. The contract is for the development of engineered microbial therapeutics for the treatment of heritable forms of glioma, a type of brain cancer. The work is focused on demonstrating technical feasibility and proof-of-concept for this therapeutic technology....
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (DHHS), to Theranano LLC, a small disadvantaged, woman-owned business. The $300,000 fixed-price contract is for research on the sustained delivery of PARP inhibitors for cancer chemoprevention. This SBIR contract was issued under the DHHS/NIH/CDC SBIR Contract Solicitation PHS 2018-1, which sought proposals from small...
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Nomocan Pharmaceuticals LLC, a for-profit limited liability company, for $354,959. The contract is for the development of a therapeutic technology, device, or diagnostic technology to treat, detect, or diagnose pediatric cancers and rare cancers with survival rates below 50%. The contract has a firm fixed-price pricing type...
This is a $398,604.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded to Infotech Soft, Inc. (a woman-owned for-profit organization) by the National Cancer Institute. The contract is for the development of quantitative imaging software tools to assist with cancer diagnosis and treatment planning. The contract is a definitive, firm fixed-price agreement, indicating a well-defined scope of work. This SBIR award is part of the National Cancer Institute's efforts to...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Pieces Technologies Inc., a small business, under the Small Business Innovation Research (SBIR) Phase II program. The contract, worth $1,999,994.00, is for the project titled &quot;Passive and Active AI Screening for Social Determinants of Health and Interventions to Improve Outcomes in the Cancer Patient Population.&quot; The contract has a period of performance from September 16,...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), to Lucidact Inc., a minority-owned and disadvantaged small business located in Los Angeles, CA. The $454,524 fixed-price contract is for the development of a digital tool to integrate cancer prevention within primary care, as part of the broader SBIR program objectives to stimulate technological innovation and strengthen the...

This is a $299,500 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Utter Therapeutics Inc., a woman-owned small business, to develop split, conditionally active peptidomimetics of interleukin-12 (IL-12) for the treatment of rare pediatric diffuse intrinsic pontine glioma (DIPG). The contract is a Firm Fixed Price Definitive Contract with an ultimate completion date of August 14, 2025. This award is part of the NCI SBIR Innovative Concept Award Program, which seeks to support the development of innovative therapeutic and diagnostic technologies for pediatric and rare cancers.

Generated 2/20/25, 9:34 AM